{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:45:00Z","timestamp":1791999900543,"version":"4.4.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmd.2026.100355","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:24:14Z","timestamp":1782861854000},"page":"100355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically based pharmacokinetic modeling of the unusual kinetics of ketoconazole due to nonlinear liver binding and metabolism in rats"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9906-5212","authenticated-orcid":false,"given":"Hee Eun","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keumhan","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfen","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Sandy","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dmd.2026.100355_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.2042-7158.2010.01202.x","article-title":"Mechanism of cytochrome P450-3A inhibition by ketoconazole","volume":"63","author":"Greenblatt","year":"2011","journal-title":"J Pharm Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100355_bib2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/dmd.106.009738","article-title":"Inhibition of UDP-glucuronosyltransferase 2B7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive model","volume":"34","author":"Takeda","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100355_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/004982500237541","article-title":"Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450","volume":"30","author":"Sai","year":"2000","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.dmd.2026.100355_bib4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archinte.1984.00350170237037","article-title":"Fatal hepatitis associated with ketoconazole therapy","volume":"144","author":"Duarte","year":"1984","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.dmd.2026.100355_bib5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00204-006-0116-y","article-title":"Repeated 28-day oral toxicity study of ketoconazole in rats based on the draft protocol for the \"Enhanced OECD Test Guideline No. 407\" to detect endocrine effects","volume":"80","author":"Shin","year":"2006","journal-title":"Arch Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100355_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/0049825031000072243","article-title":"Hepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding","volume":"33","author":"Rodriguez","year":"2003","journal-title":"Xenobiotica"},{"issue":"6298","key":"10.1016\/j.dmd.2026.100355_bib7","first-page":"1058","article-title":"Hepatitis and ketoconazole therapy","volume":"283","author":"Macnair","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.dmd.2026.100355_bib8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/jcph.711","article-title":"Ketoconazole-associated liver injury in drug-drug interaction studies in healthy volunteers","volume":"56(10)","author":"Banankhah","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2026.100355_bib9","unstructured":"EMA\/39408\/2010. Press Office. Press release. European Medicines Agency recommends suspension of marketing authorisations for sibutramine."},{"key":"10.1016\/j.dmd.2026.100355_bib10","article-title":"FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. Drugs","volume":"16","year":"2013","journal-title":"October"},{"issue":"5","key":"10.1016\/j.dmd.2026.100355_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/clpt.2014.41","article-title":"Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies","volume":"95","author":"Ke","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dmd.2026.100355_bib12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/chir.20669","article-title":"Nonlinear stereoselective pharmacokinetics of ketoconazole in rat after administration of racemate","volume":"21","author":"Hamdy","year":"2009","journal-title":"Chirality"},{"issue":"3","key":"10.1016\/j.dmd.2026.100355_bib13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1023\/A:1018996524141","article-title":"Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver","volume":"10","author":"Matthew","year":"1993","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.dmd.2026.100355_bib14","first-page":"1334","article-title":"Effect of pH on disintegration and dissolution of ketoconazole tablets","volume":"40","author":"Carlson","year":"1983","journal-title":"Am J Hosp Pharm"},{"issue":"12","key":"10.1016\/j.dmd.2026.100355_bib15","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11095-011-0506-6","article-title":"Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults","volume":"28","author":"Psachoulias","year":"2011","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100355_bib16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/bdd.2058","article-title":"The absorption kinetics of ketoconazole plays a major role in explaining the reported variability in the level of interaction with midazolam: Interplay between formulation and inhibition of gut wall and liver metabolism","volume":"38","author":"Liu","year":"2017","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmd.2026.100355_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejps.2016.12.017","article-title":"Prediction of ketoconazole absorption using an updated in vitro transfer model coupled to physiologically based pharmacokinetic modelling","volume":"100","author":"Ruff","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100355_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/acs.molpharmaceut.6b00469","article-title":"Comment on \u2033In Silico Modeling of gastrointestinal drug absorption: predictive performance of three physiologically-based absorption models","volume":"14","author":"Turner","year":"2017","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.dmd.2026.100355_bib19","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1021\/acs.molpharmaceut.7b00406","article-title":"Model-Based analysis of biopharmaceutic experiments to improve mechanistic oral absorption modeling: an integrated in vitro in vivo extrapolation perspective using ketoconazole as a model drug","volume":"14","author":"Pathak","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmd.2026.100355_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejpb.2023.06.002","article-title":"The effects of degree and duration of supersaturation on in vivo absorption profiles for highly permeable drugs, dipyridamole and ketoconazole","volume":"189","author":"Higashino","year":"2023","journal-title":"Eur J Pharmaceut Biopharm"},{"issue":"4","key":"10.1016\/j.dmd.2026.100355_bib21","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1021\/acs.molpharmaceut.4c01299","article-title":"Impact of composition of lipid-based formulations on first-pass drug metabolism after oral administration","volume":"22","author":"Tanaka","year":"2025","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.dmd.2026.100355_bib22","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1023\/A:1018918917046","article-title":"Disposition of azole antifungal agents. III. Binding of fluconazole and other azoles in rat liver","volume":"11","author":"Ervine","year":"1994","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100355_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0090-9556(24)14917-3","article-title":"Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver","volume":"27","author":"Yamano","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100355_bib24","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0090-9556(24)14922-7","article-title":"Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P-450 in rats","volume":"27","author":"Yamano","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100355_bib25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/187231209789352085","article-title":"Revisiting the metabolism of ketoconazole using accurate mass","volume":"3","author":"Fitch","year":"2009","journal-title":"Drug Metab Lett"},{"issue":"3","key":"10.1016\/j.dmd.2026.100355_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/ijms18030621","article-title":"Revisiting the metabolism and bioactivation of ketoconazole in human and mouse using liquid chromatography-mass spectrometry-based metabolomics","volume":"18","author":"Kim","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100355_bib27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1124\/jpet.102.035972","article-title":"In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat","volume":"302","author":"Kotegawa","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100355_bib28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0090-9556(25)06833-3","article-title":"The disposition and pharmacokinetics of ketoconazole in the rat","volume":"15","author":"Remmel","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100355_bib29","series-title":"Ketoconazole in the Management of Fungal Disease","first-page":"55","article-title":"Ketoconazole: pharmacological profile","author":"Heel","year":"1982"},{"key":"10.1016\/j.dmd.2026.100355_bib30","first-page":"177","article-title":"The kinetics of ketoconazole in animals and man","volume":"1","author":"Gascogaine","year":"1987","journal-title":"Clin Res Rev"},{"issue":"2-3","key":"10.1016\/j.dmd.2026.100355_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF00570136","article-title":"Dose and sex-dependent disposition of ketoconazole in rats","volume":"62","author":"Sjoberg","year":"1988","journal-title":"Arch Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100355_bib32","first-page":"14","article-title":"First-pass metabolism of midazolam by the human intestine","volume":"60","author":"Paine","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100355_bib33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","article-title":"Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism","volume":"59","author":"Thummel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"3-4","key":"10.1016\/j.dmd.2026.100355_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1081\/DMR-120000653","article-title":"The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism","volume":"33","author":"Fisher","year":"2001","journal-title":"Drug Metab Rev"},{"issue":"5","key":"10.1016\/j.dmd.2026.100355_bib35","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie\u201d","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100355_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/0049825021000022348","article-title":"Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes","volume":"33","author":"Takemoto","year":"2003","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.dmd.2026.100355_bib37","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1124\/dmd.105.009035","article-title":"Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine","volume":"34","author":"Martignoni","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"1-2","key":"10.1016\/j.dmd.2026.100355_bib38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijpharm.2009.05.044","article-title":"Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10","volume":"378","author":"Mizuma","year":"2009","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.dmd.2026.100355_bib39","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1002\/jps.22568","article-title":"First-pass metabolism via UDP-glucuronosyl-transferase: a barrier to oral bioavailability of phenolics","volume":"100","author":"Wu","year":"2011","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100355_bib40","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3109\/00498254.2012.684104","article-title":"Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats","volume":"42","author":"Vuppugalla","year":"2012","journal-title":"Xenobiotica"},{"issue":"9","key":"10.1016\/j.dmd.2026.100355_bib41","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/jcph.1619","article-title":"A novel study design using continuous intravenous and intraduodenal infusions of midazolam and voriconazole for mechanistic quantitative assessment of hepatic and intestinal inhibition","volume":"60","author":"Li","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100355_bib42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/mp700135a","article-title":"Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms","volume":"4","author":"Joseph","year":"2007","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.dmd.2026.100355_bib43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1007548905772","article-title":"Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation","volume":"17","author":"Doherty","year":"2000","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.dmd.2026.100355_bib44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0090-9556(24)15132-X","article-title":"A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism","volume":"28","author":"Cong","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100355_bib45","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1124\/dmd.116.069542","article-title":"Metabolite kinetics: the segregated flow model for intestinal and whole body physiologically based pharmacokinetic modeling to describe intestinal and hepatic glucuronidation of morphine in rats in vivo","volume":"44","author":"Yang","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100355_bib46","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/00498254.2018.1523489","article-title":"Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase","volume":"49","author":"Konishi","year":"2019","journal-title":"Xenobiotica"},{"issue":"10","key":"10.1016\/j.dmd.2026.100355_bib47","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1080\/00498254.2018.1540805","article-title":"Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes","volume":"49","author":"Patel","year":"2019","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.dmd.2026.100355_bib48","article-title":"Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions","volume":"34","author":"Umehara","year":"2019","journal-title":"Drug Metab Pers Ther"},{"issue":"5-6","key":"10.1016\/j.dmd.2026.100355_bib49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/bdd.2184","article-title":"Theoretical consideration of the properties of intestinal flow models on route-dependent drug removal: segregated flow (SFM) vs. traditional (TM)","volume":"40","author":"Noh","year":"2019","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmd.2026.100355_bib50","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/j.1552-4604.1986.tb02952.x","article-title":"Metabolic first-pass effect","volume":"26","author":"Pang","year":"1986","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100355_bib51","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1124\/dmd.31.12.1507","article-title":"Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series)","volume":"31","author":"Pang","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100355_bib52","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2174\/138920010794328931","article-title":"PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism","volume":"11","author":"Fan","year":"2010","journal-title":"Curr Drug Metab"},{"issue":"9","key":"10.1016\/j.dmd.2026.100355_bib53","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.xphs.2017.05.003","article-title":"The constraints, construction, and verification of a strain-specific physiologically based pharmacokinetic rat model","volume":"106","author":"Musther","year":"2017","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.dmd.2026.100355_bib54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonespecific brain and plasma protein binding on CNS exposure: implications of rational drug disocvery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100355_bib55","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0022-3565(25)13245-X","article-title":"Sequential metabolism of salicylamide exclusively to gentisamide 5-glucuronide and not gentisamide sulfate conjugates in single-pass in situ perfused rat liver","volume":"253","author":"Xu","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100355_bib56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF01061478","article-title":"Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics","volume":"13","author":"Harashima","year":"1985","journal-title":"J Pharmacokinet Biopharm"},{"issue":"11","key":"10.1016\/j.dmd.2026.100355_bib57","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1124\/dmd.114.058784","article-title":"Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin, and itraconazole are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1","volume":"42","author":"Higgins","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100355_bib58","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and Sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.dmd.2026.100355_bib59","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.dmd.2026.100355_bib60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200847040-00004","article-title":"Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis","volume":"47","author":"Peters","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmd.2026.100355_bib61","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/01.RES.4.4.419","article-title":"Distribution of blood (Fe 59) and plasma (I 131) volumes of rats determined by liquid nitrogen freezing","volume":"4","author":"Everett","year":"1956","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100355_bib62","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/toxsci\/kfi119","article-title":"Development of a physiologically based pharmacokinetic model for ethylene glycol and its metabolite, glycolic acid, in rats and humans","volume":"85","author":"Corley","year":"2005","journal-title":"Toxicol Sci"},{"issue":"4","key":"10.1016\/j.dmd.2026.100355_bib63","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.108.023788","article-title":"Physiologically based pharmacokinetics of matrine in the rat after oral administration of pure chemical and ACAPHA","volume":"37","author":"Gao","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100355_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1011527125570","article-title":"Assessment of actual significance levels for covariate effectsin NONMEN","volume":"28","author":"W\u00e4hlby","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"10.1016\/j.dmd.2026.100355_bib65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01061504","article-title":"Statistical estimations in pharmacokinetics","volume":"2","author":"Boxenbaum","year":"1974","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"10.1016\/j.dmd.2026.100355_bib66","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/00498254.2016.1204485","article-title":"Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver","volume":"47","author":"Iwasaki","year":"2017","journal-title":"Xenobiotica"},{"issue":"9","key":"10.1016\/j.dmd.2026.100355_bib67","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1111\/bcp.14022","article-title":"Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite","volume":"85","author":"Li","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100355_bib68","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40261-019-00764-x","article-title":"Effect of CYP3A inhibition and induction on the pharmacokinetics of suvorexant: two phase I, open-label, fixed-sequence trials in healthy subjects","volume":"39","author":"Wrishko","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"6","key":"10.1016\/j.dmd.2026.100355_bib69","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1023\/A:1018906614320","article-title":"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine","volume":"11","author":"Wrighton","year":"1994","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100355_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.25.1.1","article-title":"Influence of food on the pharmacokinetics of ketoconazole","volume":"25","author":"Daneshmend","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.dmd.2026.100355_bib71","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/pharmaceutics15020679","article-title":"A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug\u2013drug interaction perpetrators","volume":"15","author":"Marok","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.dmd.2026.100355_bib72","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/jm021012t","article-title":"Comparison of in vitro P-glycoprotein screening assays: recommen dations for their use in drug discovery","volume":"46","author":"Schwab","year":"2003","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.dmd.2026.100355_bib73","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1124\/jpet.111.179101","article-title":"1\u03b1,25-Dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid x receptor in both fxr(-\/-) and fxr(+\/+) mice and increased renal and brain efflux of digoxin in mice in vivo","volume":"337","author":"Chow","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100355_bib74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.clpt.6100230","article-title":"Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo","volume":"83","author":"Templeton","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100355_bib75","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40262-015-0352-5","article-title":"Development of a physiologically based pharmacokinetic model for itraconazole pharmacokinetics and drug\u2013drug interaction prediction","volume":"55","author":"Chen","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"20","key":"10.1016\/j.dmd.2026.100355_bib76","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.3390\/molecules27206815","article-title":"Itraconazole-induced increases in gilteritinib exposure are mediated by CYP3A and OATP1B","volume":"27","author":"Garrison","year":"2022","journal-title":"Molecule"},{"issue":"1","key":"10.1016\/j.dmd.2026.100355_bib77","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF01061775","article-title":"Nonlinear protein binding and enzyme heterogeneity: effects on hepatic drug removal","volume":"21","author":"Xu","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"10.1016\/j.dmd.2026.100355_bib78","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-3565(25)38377-1","article-title":"Effect of protein binding on 4-methylumbelliferyl sulfate desulfation kinetics in perfused rat liver","volume":"266","author":"Chiba","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.dmd.2026.100355_bib79","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1023\/A:1018966800208","article-title":"Disposition of azole antifungal agents. II. Hepatic binding and clearance of dichlorophenyl-bis-triazolylpropanol (DTP) in the rat","volume":"11","author":"Bomont","year":"1994","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.dmd.2026.100355_bib80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","article-title":"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin","volume":"64","author":"Gorski","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100355_bib81","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2125.2003.01824.x","article-title":"Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin\u2013clarithromycin interaction","volume":"56","author":"Rengelshausen","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100355_bib82","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.dmd.2026.100355_bib83","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/00498250500093786","article-title":"Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats","volume":"35","author":"Kanazu","year":"2005","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2026.100355_bib84","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/bdd.2051","article-title":"Physiologically based pharmacokinetic modeling revealed minimal codeine intestinal metabolism in first-pass removal in rats","volume":"38","author":"Noh","year":"2017","journal-title":"Biopharm Drug Dispos"}],"updated-by":[{"DOI":"10.1016\/j.dmd.2026.100391","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:52:49Z","timestamp":1791996769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0090955626006240"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100355","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based pharmacokinetic modeling of the unusual kinetics of ketoconazole due to nonlinear liver binding and metabolism in rats","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100355"}}